{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:10:19Z","timestamp":1775031019276,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T00:00:00Z","timestamp":1377216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To evaluate long\u2010term survival of the first cohort of stage\u20104 neuroblastoma patients treated with the N7 induction chemotherapy, surgery of the primary tumor and high\u2010dose chemotherapy (HDC) containing Busulfan\u2013Melphalan (Bu\u2010Mel) followed by autologous stem cell transplantation (ASCT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>From 1998 to 1999, 47 children were included in the NB97 trial and treated with induction chemotherapy according to the N7 protocol, followed by surgery of the primary tumor. HDC (Busulfan, 600\u2009mg\/m<jats:sup>2<\/jats:sup> Melphalan, 140\u2009mg\/m<jats:sup>2<\/jats:sup>) was administered in patients with partial response of metastases with no more than 3 mIBG spots. Radiotherapy was delivered to the primary tumor site when tumors displayed <jats:italic>MYCN<\/jats:italic> amplification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010nine patients received Bu\u2010Mel (83%): 23 who had achieved complete response (CR) of metastases, 20 after induction treatment and 3 after second\u2010line chemotherapy, and 16 in partial response (PR). The toxicity of the whole treatment was manageable. The main HDC related\u2010toxicity was hepatic veno\u2010occlusive disease grade\u2009&gt;\u20092 occurring in 15% of the patients. The 8\u2010year EFS of the whole cohort was 34% (95% CI, 22\u201348%). The 8\u2010year EFS of the 39 patients who received Bu\u2010Mel and ASCT was 41% (95% CI, 27\u201357%). Patients who achieved a CR of metastases at the end of induction chemotherapy had a significantly better outcome than the others (8\u2010year EFS, 52% vs. 20%; <jats:italic>P<\/jats:italic>\u2009=\u20090.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The long\u2010term results of this first prospective cohort of patients with metastatic disease treated with the N7 induction chemotherapy and HDC (Bu\u2010Mel) confirm published data with stable survival curves but with a longer follow\u2010up. Pediatr Blood Cancer 2014;61:977\u2013981. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.24713","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T10:10:45Z","timestamp":1377252645000},"page":"977-981","source":"Crossref","is-referenced-by-count":46,"title":["Long\u2010term results of the combination of the N7 induction chemotherapy and the busulfan\u2010melphalan high dose chemotherapy"],"prefix":"10.1002","volume":"61","author":[{"given":"Dominique","family":"Valteau\u2010Couanet","sequence":"first","affiliation":[{"name":"Department of Pediatric and Adolescent Oncology Institut Gustave Roussy Villejuif France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010C\u00e9cile","family":"Le Deley","sequence":"additional","affiliation":[{"name":"Biostatistics Unit Institut Gustave Roussy Villejuif France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Bergeron","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Centre L\u00e9on B\u00e9rard Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Ducassou","sequence":"additional","affiliation":[{"name":"Onco\u2010Hematology Department CHU Pellegrin Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Michon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Institut Curie Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Rubie","sequence":"additional","affiliation":[{"name":"Onco\u2010Hematology Unit CHU Purpan Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwenael","family":"Le Teuff","sequence":"additional","affiliation":[{"name":"Biostatistics Unit Institut Gustave Roussy Villejuif France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Coze","sequence":"additional","affiliation":[{"name":"Aix\u2010Marseille Univ et APHM, H\u00f4pital d'Enfants de La Timone, Service d'H\u00e9matologie\u2010Oncologie P\u00e9diatrique Marseille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Plantaz","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit CHU Grenoble France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Sirvent","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit CHU Montpellier France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanine","family":"Bouzy","sequence":"additional","affiliation":[{"name":"Biostatistics Unit Institut Gustave Roussy Villejuif France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Chastagner","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit CHU Nancy Hopital d'enfants Vandoeuvre France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Oncology Institut Gustave Roussy Villejuif France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.054"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.101"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2607"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70291-6"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910143411601"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20219"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701737"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.2062"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.8.1466"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950190415"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002"},{"key":"e_1_2_6_13_1","volume-title":"WHO handbook for reporting results of cancer treatment","author":"World Health Organization","year":"1979"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.10.1562"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.953"},{"key":"e_1_2_6_16_1","doi-asserted-by":"crossref","unstructured":"LadensteinRL PoetschgerU LukschR. et al.Busulphan\u2010melphalan as a myeloablative therapy (MAT) for high\u2010risk neuroblastoma: Results from the HR\u2010NBL1\/SIOPEN trial. Presented at the ASCO'11 Annual Meeting. Chicago IL June 3\u20137 2011.","DOI":"10.1200\/jco.2011.29.15_suppl.2"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8925"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.468"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.12.3433"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24713","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.24713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T22:29:10Z","timestamp":1696458550000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,23]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1002\/pbc.24713"],"URL":"https:\/\/doi.org\/10.1002\/pbc.24713","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,23]]}}}